ARQ 501 in Subjects With Cancer

Phase 1

Completed

• Conditions: Cancer

• Registration Number: NCT00075933
• Lead Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Brief Summary

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT).

ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Study First Submitted: 2004-01-12
• Study First Submitted QC: 2004-01-12
• Study First Posted: 2004-01-13
• Primary Completion: 2007-01
• Study Completion: 2007-01
• Status Verified: 2009-04
• Last Update Submitted: 2009-04-27
• Last Update Posted: 2009-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (2)

Dana Farber/Partners CancerCare Inc; 🇺🇸 Boston, Massachusetts, United States

Mary Crowley Medical Research Center; 🇺🇸 Dallas, Texas, United States